Table 2 Results of therapy in patients with advanced breast carcinoma treated with regimens comprising 5-fluorouracil, folinic acid, and pyridoxine in tandem.

From: Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma

Category^a	Patient	Regimens^b comprising FUra, FA and PN in tandem given in succession from A to C [No. of courses of each regimen]			Median dose of PN^c	Time to response^d (Mo.)	Antitumor activity			CA15-3 start/after treatment (U/ml)	PFSⁱ (Mo.)
Category^a	Patient	A	B	C	Median dose of PN^c	Time to response^d (Mo.)	RECIST^e	PERCIST^f	Pathologic (AJCC)^g	CA15-3 start/after treatment (U/ml)	PFSⁱ (Mo.)
I	1	AVCF [6]	TCbF [6]	VCbF [10]	3	4.0	− 100	− 100	–	166/24	22+
	2	FAC [4]	TCbF [4]	VCbF [5]	1	4.5	− 100	− 100	–	–	45+
	3	AVCF [4]	TCbF [5]	VCbF [3]	1	4.6	− 100	− 100	ypT0N0	–	44+
	4	FAC [6]	TCbF [6]	VCbF [6]	3	2.3	− 98	− 100	–	272/29	21+
	5	VCbF [3]	TCbF [6]	VCbF [21]	2	4.7	− 98	− 100	–	2212/123	22
	6	AVCF [6]	TCbF [1]	VCbF [8]	3	3.3	− 96	− 100	ypT1bN0	–	17+
	7	AVCF [6]	TCbF [5]	VCbF [1+]	3	2.4	− 93	− 94	–	1017/31	9+
	8	AVCF [6]	TCbF [7]	VCbF [6]	2	4.4	− 89	− 87	–	849/24	51
	9^h	TCbF [5]	VCbF [6]		2.5	3.4	− 89	− 84	ypN1aM0^h	–	33+
	10	AVCF [5]	TCbF [9]		1	5.3	− 79	− 85	ypT1cN1a	–	38
	11^h	TCbF [8]	VCbF [6]		1	3.9	− 64	− 50	ypN0M1^h	–	55+
	12	TCbF [7]			1	2.5	− 62	Na	–	782/73	7
II	13	TCbF [8]	VCbF [3]		1	3.9	− 100	− 100	ypT0N0	62/25	44+
	14	TCbF [8]	VCbF [4]		2	1.7	− 100	− 100	ypT0N0	–	71+
	15	TCbF [8]	VCbF [4]		2	4.2	− 100	− 93	ypT0N0	–	67+
	16	TCbF [9]	VCbF [15]		3	2.4	− 100	− 100	ypT1bN0	14,750/29	27
	17	TCbF [12]	VCbF [39]		1	8.4	− 98	− 100	–	–	70+
	18	TCbF [8]	VCbF [21]		3	2.0	− 98	Na	–	422/26	23+
III^h	19	TCbF [9]			2	2.1	Na	− 100	–	152/79	54
	20	TCbF [8]			1	2.8	− 100	− 100	–	1272/12	13
	21	VCbF [18]			2	2.4	− 100	− 93	–	116/29	34
	22	TCbF [12]			3	6.8	− 94	− 47	–	126/46	12
	23	VCbF [12]			1	2.6	− 91	− 100	–	72/13	28+
	24	TCbF [18]			2	5.4	− 88	− 100	–	101/14	30ⁱ
	25	TCbF [23]			1	3.1	− 88	− 100	–	–	15
	26	TCbF [21]			2	3.3	− 81	− 91	–	–	27
	27	TCbF [8]			1	–	45	Na	–	–	–

^aCategories comprise I, previously untreated patients whose tumors did not overexpress HER2 (1–12); II, previously untreated patients whose tumors overexpressed (3+) HER2 (13–18); and III, previously treated patients whose tumors did not overexpress HER2 (19–27).
^bComposition of regimens is described in text.
^cMedian dose of PN preceding each injection of FUra and FA (× 10³ mg/day).
^dTime to attain antitumor response, i.e., reduction in sum of diameters by ≥ 30%.
^ePatients who attained a PR accompanied by disappearance of most metastases had RECIST (Response Evaluation Criteria in Solid Tumors) values calculated by size comparison of persisting tumors at the time of assessment with these same tumors before treatment.
^fPercent variation in peak standard ¹⁸FDG uptake value normalized by lean body mass (SUL_peak) assessed by PET scan (PERCIST; Positron Emission Tomography (PET) Response Evaluation Criteria in Solid Tumors).
^gPathologic response was assessed by mastectomy or by locoregional resection with eradication intent in patients with prior mastectomy.
^hPatient with prior mastectomy.
ⁱEFS time in Patient 24. Na not assessed.

Back to article page

Table 2 Results of therapy in patients with advanced breast carcinoma treated with regimens comprising 5-fluorouracil, folinic acid, and pyridoxine in tandem.

Search

Quick links